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ABSTRACT 
 
Background 
Cancer survivors frequently report a range of unmet psychological and supportive 
care needs; these often continue after treatment has finished, and are predictive of 
psychological distress and poor health-related quality of life. Online interventions 
demonstrate good efficacy in addressing these concerns and are more accessible 
than face to face interventions. Finding My Way is an online, psycho-educational and 
cognitive behaviour therapy intervention for cancer survivors developed in Australia. 
Previous trials have demonstrated Finding My Way to be acceptable, highly adhered 
to, and effective in reducing the impact of distress on quality of life, whilst leading to 
cost-savings through health-resource use reduction.  
 
Objectives 
Our study will adapt the Australian Finding My Way website for a UK cancer care 
context, and then undertake a single-blinded, randomised controlled trial (RCT) of 
Finding My Way UK against a treatment-as-usual waitlist control. 
 
Methods 
As much as possible, our trial design replicates the existing Australian RCT of 
Finding My Way. Following a comprehensive adaptation of the web-resource, we will 
recruit 294 participants (147 per study arm) from across clinical sites in North West 
England and North Wales. Participants will: (i) have been diagnosed with cancer of 
any type in the last six months, (ii) have received anti-cancer treatment with curative 
intent, (iii) be over 16 years of age, (iv) be proficient in English and (v) have access 
to the internet and an active email address. Participants will be identified and 
recruited through the NIHR Clinical Research Network. Measures of distress, quality 
of life, and health economic outcomes will be collected using a self-report online 
questionnaire at baseline, mid-treatment, post-treatment and both three- and six-
month follow-up. Quantitative data will be analysed using intention-to-treat Mixed-
Model Repeated Measures analysis. Embedded semi-structured qualitative 
interviews will probe engagement with, and experiences of using, Finding My Way 
UK and suggestions for future improvements. 
 
 
 
Results 
Website adaptation work was completed in January 2021. A panel of cancer 
survivors and healthcare professionals provided feedback on the test version of 
Finding My Way UK. Feedback was positive overall, though minor updates were 
made to website navigation, inclusivity, terminology and the wording of the Improving 
Communication and Sexuality and Intimacy content. Recruitment for the clinical trial 
commenced in April 2021. We aim to report on findings from mid 2023. 
  
Conclusions 
Replication studies are an important aspect of the scientific process, particularly in 
psychological and clinical trial literatures, and especially in different geographical 
settings. Prior to replicating the Finding My Way trial in the UK setting, some content 
updating was required. If Finding My Way UK now replicates Australian findings, we 
will have identified a novel and cost-effective method of psychosocial care delivery 
for UK cancer survivors.  
 
 
Trial Registration 
The Finding My Way UK Trial is registered on the ISRCTN (Reference: 
ISRCTN14317248; Date Registered 08/04/2021). 
 
 
Keywords: Cancer, Survivorship, Psychosocial Intervention, Digital Health, Quality 
of Life, Protocol 
  
INTRODUCTION 
 
UK cancer survivorship rates have increased such that up to 57% of UK cancer 
patients can now expect to survive for 10 years [1]. There is regional discrepancy, 
however, and survival rates differ across geographic region and treatment centre 
catchment areas. Recently published screening studies suggest prevalence of distress 
of up to 41.5% in adolescents and young adults [2] and 46% in adult [3] cancer 
populations. Anxiety, depression or other psychological co-morbidities impact 
significantly on quality of life [4]. If left untreated, distress can escalate [5], and a 
pooled analysis of 163,363 cancer survivors demonstrated that distress in some cancer 
groups predicted higher mortality risk, even after controlling for age, sex, education, 
socioeconomic status, body mass index, smoking, and alcohol intake [6]. Our own 
work in people diagnosed with the four most common cancers demonstrates that 
distress can be predicted by cognitive and emotional response to diagnosis [4], and 
that psychological variables, such as psychological flexibility, are predictive of distress-
related outcomes independent of clinical and sociodemographic characteristics [7]. 
Unmet psychological and supportive care needs are prevalent in cancer survivors  [8–
11]; we have found that 54% of haematological patients report five or more unmet 
supportive care needs [10] and 46% of colorectal patients report at least one specific 
psychological need [12]. There is therefore a crucial need to develop effective 
interventions to manage psychological distress in cancer survivors. 
A recent review of psychological interventions for cancer patients [13] 
concluded that whilst Cognitive Behavioural Therapy (CBT) remains the gold-standard 
treatment choice, we need more methodologically robust research to determine 
efficacy and scope for implementation. There is an excess of small-scale studies where 
fully powered trials, exploring moderators and mediators of effects, are needed. 
Research in non-breast cancer populations was recommended, along with inclusion of 
health economic outcomes to provide powerful data for clinical service commissioners. 
Given the high cost and time investment that goes into developing new intervention 
content and delivery formats, one effective strategy is to adapt existing interventions 
rather than to waste finite resources developing novel and competing interventions. 
Furthermore, replication studies are important to demonstrate consistency and 
generalisability of outcomes, and are recommended in response to the replication crisis 
in psychology [14].  
A recent systematic review highlighted that one of the top barriers to accessing 
psychosocial support identified by cancer patients is difficulty with transport to the 
health service delivery centre [15], though other types of access issues have been 
reported elsewhere too. In order to overcome this barrier, recent research has 
increasingly investigated the feasibility and efficacy of online psychosocial interventions 
for cancer patients [16]. Online delivery methods are also recommended as a way to 
overcome the expense of delivering psychological support [17–19]. Given recent 
increases in home-based internet access in the UK, especially through the rapid 
development and uptake of smart-phone and tablet technologies [20], web-based 
interventions may address access issues by widening the potential pool of beneficiaries 
[21]. They also overcome the stigma associated with overtly seeking psychological 
support [22], and (as demonstrated through the current Covid-19 pandemic) are a way 
to ensure continuation of service where there may be barriers to continued face-to-face 
care [23]. Digital psychosocial interventions confer many potential benefits, including 
greater convenience, reduced burden on cancer patients and carers, and reduced 
resource use and healthcare costs, as compared to traditional face-to-face 
interventions [24]. However, most clinically measurable differences associated with 
online psychosocial interventions for this population fail to meet statistical 
significance, a phenomenon likely attributable to study design rather than a lack of 
real effect [16]. Additionally, a need has been identified for interactive treatment 
components in order to mitigate the lack of face-to-face interaction. 
One of the most promising online interventions for cancer survivors is Finding 
My Way (FMW), developed by Beatty and colleagues in Australia [25]. FMW is the 
second iteration of a six-module, online, self-guided intervention, initially titled Cancer 
Coping Online  [26]. It uses psycho-educational and CBT-based theoretical 
frameworks, and includes exercises from third-wave approaches, for example, 
mindfulness and values clarification work exercises. Early pilot work demonstrated 
benefits on physical functioning and distress outcomes [18]. Whilst between-group 
differences were not replicated in a recent, larger, randomised controlled trial (RCT) 
[27], this trial compared the intervention group with a low-dose active control group 
(identical psychoeducation and video-based content), with both groups reporting 
reductions in distress over time. As such, the lack of significant between-group findings 
may be related more to overlap of content between treatment groups rather than lack 
of efficacy in the online intervention group. Promisingly, this recent RCT found 
significantly better emotional functioning and lowered healthcare utilisation in the FMW 
arm, demonstrating both (a) that distress had less functional impact on quality of life, 
and (b) health service cost-reduction [27]. Adherence was also high [26]. A number of 
replication studies of FMW are underway across the world, and FMW has been 
adapted for women with advanced breast cancer [28], demonstrating the flexibility of 
the programme for different demographic groups and clinical contexts. As such, FMW 
is a good candidate for effective support in the UK cancer care setting, but some 
adaptation was necessary prior to implementation. This paper reports on our work 
undertaken to adapt the intervention, and the protocol for the ongoing RCT which tests 
its efficacy in a UK NHS setting. We aim to test (a) whether outcome effects are 
replicated and/or improved and (b) whether intervention uptake, use and 
acceptability meet feasibility thresholds for implementation into standard care. 
 
METHODS 
 
Trial Design  
We will conduct a single-blinded RCT of FMW-UK compared against treatment 
as usual control. Mixed-methods data collection—using self-report questionnaires, 
quantitative clinical data extraction, and in-depth interviews—will be undertaken to 
investigate efficacy and acceptability. Where possible, trial design and outcomes 
replicate key features of Beatty et al.’s [27] Australian RCT of FMW.  
All aspects of study design and governance are planned to involve the expert 
voice of people affected by cancer as active partners in the research study. The study 
is hosted by the University of Chester with scrutiny provided by a Trial Steering Group 
comprising: grant co-applicants (including a cancer survivor co-applicant), the local 
research team, a patient, a carer and a healthcare professional stakeholder 
representative. The Steering Group meets twice per year, with a smaller Project 
Management Group meeting bi-monthly to provide operational oversight.  
 
The FMW-UK intervention 
FMW-UK is designed as a six-week, self-administered, modularised, web-based 
programme. Written and video-based information about a range of cancer care topics 
and the provision of psychological intervention materials are supplemented with 
testimonials from cancer survivors sharing their experiences and advice. Interactive 
exercises, including worksheets, assessment tools, and pre-recorded self-guided 
mindfulness meditations are included; these experiential components are likely 
important to boost efficacy [27]. The modules, released one per week, address 
common psychosocial concerns and unmet needs among cancer survivors and are 
structured around: (1) treatment and communication with treatment teams; (2) coping 
with physical symptoms and side effects; (3) managing distress; (4) challenges to 
identity, body image and sexuality; (5) social support and family concerns; and, (6) 
issues that arise after treatment. On first accessing the site, users are prompted to 
make a choice about which order they wish to access modules in to meet their self-
determined need priorities. A booster module is released one month after completion, 
which re-caps programme content and signposts back to earlier modules.   
 
Contextual adaptation 
We began our adaptation of FMW with our local research team reviewing the 
information provided, to determine which aspects needed changing for the UK cancer 
care setting. This included referencing standard care pathways and services available 
to UK cancer patients, and adapting some terminology to avoid confusion. We 
reviewed all website content to identify Australian-specific resources and treatment 
information and then worked with our steering group (including academics, clinicians 
and patient and carer representatives) to systematically identify equivalent British 
information and sign-posting resources with which to replace these. Our adaptation 
plan was then approved by the Trial Steering Group. 
 
Video content 
Each module includes an information video and in the Australian version these 
were recorded by either an oncologist or a psychologist. In re-recording these videos, 
we chose to include a wider variety of professionals, including psychologists, 
oncologists, a surgeon, and a manager of a local cancer support centre with a cancer-
nursing background. This change was undertaken to (a) better represent the 
multidisciplinary nature of cancer care in the UK setting, and (b) as a tool to increase 
diversity and inclusivity throughout the programme. These videos were scripted, 
including only minor edits from the Australian original content.  
Although much of the content of the cancer survivor testimonial videos was 
applicable to a UK-based cohort, we produced a new set of videos with UK cancer 
survivors to maximise the extent to which our participants would connect and affiliate 
with the stories and experiences shared. Using our existing networks, advocacy groups 
and advertisements placed on social media, we recruited nine cancer survivors from 
across North Wales and the North West of England (see Table 1) and undertook 
individual video-recorded interviews with each, between August and September 2020. 
Survivors were selected to maximise diversity of interviews, both demographically and 
with regard to cancer experiences. Video interviews were unscripted but followed a 
standard question schedule (see Box 1) that had been used in development of the 
original Australian website and that was provided to interviewees in advance for 
preparation purposes. Videos were reviewed by three members of the team to select 
clips to be edited into thematically-linked videos for each module.  
 
Table 1. Characteristics of the cancer survivors who participated in video 
interviews for the FMW-UK website 
 
Name* Gender Age  Cancer Type Time 
since 
diagnosis 
Janet Female 64 years Bowel 3 years 
Martin Male 66 years Prostate >10 years 
Sue M Female 56 years Breast 6 years 
Dylan Male 47 years Bladder 2 years 
Terry Male 74 years Lung >10 years 
Sue H Female 61 years Breast 4 years 
Bernadette Female 52 years Breast 1 year 
Sophie Female 24 years Burkitt’s Lymphoma 4 years 
Babz Male 31 years Non-Hodgkin’s Lymphoma >10 years 
*Participants were given the choice to use their actual name or pseudonym.  
 
Video interview participants (survivors and health care professionals) were 
reimbursed for their time and travel expenses, as is good practice for patient and public 
involvement in health research [29]. They all signed a consent form to permit ongoing 
use of their video content after the trial is complete. Given that these interviews took 
place during the Covid-19 pandemic, a rigorous health and safety assessment was 
undertaken, and appropriate infection control measures were implemented. Video 
recordings (and later editing work) were undertaken by the research team given the 
difficulties inherent in commissioning this work to an external company through the 
intermittent implementation of Covid-19 related social distancing in the UK during this 
time.  
 
 
Box 1: Question schedule for video interviews with cancer survivors to create FMW-UK 
intervention content   
 
1. What issues came up for you after diagnosis (and during treatment) in terms of making 
decisions about treatment, or when discussing things with your medical treatment team? 
2. During treatment, what was your most pressing physical need / concern? 
3. During treatment, what was your most pressing emotional need / concern? 
4. Some people find that many of their roles change during treatment, that they aren’t able to do 
the tasks and activities they usually do, which then affects the way they feel about themselves. 
During treatment how did your roles change and how did this affect you?  
5. During treatment, what was your most pressing social need? What surprised you? 
6. What things were challenging for you with your family life? 
7. If you could give one piece of advice to another person with cancer, what would it be? 
8. Over the process of treatment, what was the most confusing issue for you? 
9. What did you do to mark the end of your treatment? 
10. What advice would you give to other cancer survivors about staying healthy? 
11. Some people say that having cancer gave them an opportunity to learn something new 
about life or themselves. What is the one learning experience you had that you would not have 
had if you did not have cancer? 
12.Were there any other questions you thought we should have asked? 
 
 
Evidence review 
Given that the Australian FMW content was last updated in 2013, we reviewed 
all research claims made throughout the website content and conducted literature 
reviews to identify which claims were still upheld by recent research. We subsequently 
updated the references for some evidence statements, and edited claims that were no 
longer conclusively supported by the current evidence base. In brief, this included: 
• De-emphasising the strength of claims made about the benefits of emotional 
expression and therapeutic writing [30,31]. 
• Updated references in relation to benefit finding and positive adjustment [7]. 
• Updated reference to support our recommendation for the benefits of 
mindfulness-based exercises [32]. 
• Inclusion of more recent references in relation to the impact of dyadic 
influences on adjustment between patients and their partners [33], and in 
relation to the benefits of information on distress levels in close others of 
people being treated for cancer [34]. 
• Reframing of claims made about the benefits of religious and spiritual beliefs 
to confirm that these may be helpful for those with existing beliefs, but so that 
we’re not seen as advocating a change in practices or beliefs. 
 
Web-hosting and user-testing 
We commissioned an independent web-design company to adapt the original 
FMW web-based framework for our purposes. The website was designed using 
Wordpress v.5.7.1 and is hosted through Kinsta. Videos are uploaded to YouTube with 
embedded links provided at relevant points of the website. The videos are not publicly 
listed to prevent access outside of the trial, and the FMW-UK website is restricted to 
only those with a username and password provided by our team.  
Once an initial test website had been created, we recruited a panel of four 
cancer survivors and three healthcare professionals to provide user feedback, who 
were each financially compensated for their input. The cancer survivors were identified 
from our initial advertisement for video interview participants, and healthcare 
professionals (oncology and psychology-based) were identified from existing 
professional networks. Additional user testing was undertaken by the Trial Steering 
Group. Where relevant, feedback was integrated into a final website update (see 
Results) prior to recruitment commencing.  
 
Participants 
Sample size calculation 
Calculations are based on the primary outcome of change in cancer-specific 
distress between the two patient groups. The original FMW RCT sample size 
calculation [27] used a standardised effect size of 0.35 and standard deviation of 4 
units, which equates to an absolute change in cancer distress scores of 1.4 units. This 
study observed a larger than expected standard deviation and we propose a sample 
size based on a conservative estimate of the residual standard deviation of 7 units 
accordingly (but keeping the clinically relevant difference at the aforementioned 1.4 
units). Correlation between successive measurements on the same patient are 
assumed to be high and so a conservative r = .70 is used. Sample size calculations are 
performed assuming a paired t-test using a derived standard deviation about the 
change in the primary outcome of 5.42. Assuming a patient attrition of 20% and a two-
sided alpha = 0.05, then 294 patients (147 per study arm) are required for statistical 
power of 80% [35]. We will allow up to 30% over-recruitment to mitigate the effects of 
missing data and to allow for at least minimal recruitment of less common cancer 
types. 
 
Recruitment and eligibility criteria 
Participants will be recruited from multiple NHS hospital sites across North West 
England and North Wales using NIHR Clinical Research Network Research Nurses 
(CRN RNs). Patients will be eligible to take part if they meet the following inclusion 
criteria: (a) have been diagnosed with cancer of any type in the past six months and (b) 
received anti-cancer treatment with curative intent, (c) are aged 16 years or over; (d) 
are sufficiently proficient in English to provide informed consent and use the 
programme; and (e) able to access the internet and have (or be willing to set up) an 
email address. Patients will be ineligible / excluded if they have a severe comorbidity 
considered to interfere with the individual’s ability to complete the requirements of the 
study or to provide informed consent (e.g., intellectual disability or neurological 
impairment). Nurses will complete fortnightly screening logs to provide anonymised 
information on number of patients screened, eligible and then provided with a trial 
information pack, to inform later potential implementation decisions.  
CRN RNs will screen regular multidisciplinary team (MDT) meeting records for 
eligible patients and identify when their next clinical appointment will be. The CRN RN 
will approach each patient face-to-face to tell them about the study and provide an 
information pack. Where no appointment is planned within the subsequent six weeks, 
or where face-to-face introduction would be otherwise problematic (e.g., lack of private 
space to discuss the study), our protocol permits a telephone introduction to the study. 
At the start of recruitment, records of existing MDT meetings will be retrospectively 
searched for any patients meeting eligibility criteria, though we anticipate the majority of 
our sample to be recruited through prospective recruitment over a 12-month 
recruitment period.  
Assuming a conservative 40% consent rate [27], we estimate that 735 patients 
will need to be approached to reach our target sample size. We will recruit from a 
range of cancer teams to ensure clinical diagnostic and demographic variability. 
 
Procedure 
After reading information provided by the CRN RNs, patients wishing to take 
part in the study access our study recruitment website via a link in their information 
pack. This provides a full trial information sheet and access to an online consent form. 
Once their consent is submitted, participants are redirected immediately to the baseline 
survey via Qualtrics. Participants also receive an automated email with a link to 
complete the baseline questionnaire at a later date or in a number of sittings if they 
prefer. On full completion of the baseline questionnaire, an unblinded member of the 
research team completes study arm allocation using a computerised randomisation 
allocation system using RedCap software [36]. The randomisation algorithm is set up 
to ensure equal numbers of participants in both the intervention and control arm, 
stratified by cancer diagnosis to ensure a spread of patients across both trial arms. The 
randomisation system was set-up and is overseen by the Liverpool Clinical Trials 
Centre (LCTC). Following allocation, participants are either emailed account details to 
access the FMW-UK website (intervention group), or sent a PDF copy of a site-specific 
information pack listing existing local and national sources of psychosocial support that 
they can access as part of treatment as usual (control group) (see also Figure 1). 
Control participants also have the option to receive a hard-copy of the information pack 
via post. 
Those given immediate access to FMW-UK are encouraged to log in within one 
week, study the instruction materials provided, and select the order in which they would 
like to receive access to the intervention modules (if no preference is given, participants 
receive in default numerical order). A reminder (text or phone, as preferred) is then sent 
if they have not logged in during this time. Modules are then automatically released, 
once per week; access to the booster module is also released one month after 
completion of the main programme. Regular automated email reminders are sent as 
new modules are released each week.  
 
  
Figure 1: Procedure for the FMW-UK Clinical Trial  
 
 
At the point of being informed of intervention allocation, automated email 
reminders to complete study questionnaires are set-up through Qualtrics. Text 
message or phone call reminders (as preferred) are sent where a period of seven days 
has passed without submission of any specific questionnaire. Questionnaires are 
completed at the end of the third (mid-intervention) and sixth (post-treatment) week, 
and then at three- and six-month follow-up, both timed from release of the post-
treatment questionnaire. Participants are sent a debrief sheet at this point, with control 
arm participants also then being granted access to the FMW-UK website. At this point, 
CRN RNs complete clinical data extraction from hospital records using a standard 
form; this includes information about: date of diagnosis; primary or recurrent 
diagnosis; curative or palliative treatment intent; principle treatment approach 
adopted (surgery, chemotherapy, radiotherapy, or watch-and-wait); date of the end 
of active treatment (if applicable); date of any recurrence or relapse (if applicable); 
date of death (if applicable); known referrals to mental health care teams since 
diagnosis; number of days of inpatient care since study enrolment and types of 
healthcare professionals seen during these stays; the number of outpatient visits 
since study enrolment and types of healthcare professionals seen during these visits; 
and any diagnosis tests conducted since study enrolment. As this study is registered 
on the UK NIHR Clinical Research Network Portfolio, costs for most CRN RN activity 
(both recruitment and clinical data collection) are covered by CRN Study Support 
Services, with costs for additional archiving at each site reimbursed by the clinical 
trial research grant. 
 
Measures 
We will ask participants to self-report the following demographic 
characteristics: age, gender, sexuality, ethnicity, employment, education, marital 
status, household income and postcode (to calculate Index of Multiple Deprivation). 
The following list of self-report questionnaires are then administered throughout the 
study (see Table 2 for timing for each). We have sought to use measures consistent 
with the original Australian FMW study in order to most closely replicate this previous 
clinical trial. Exceptions include: (i) a briefer measure was identified to reduce 
participant burden (e.g., using the Psychological Impact of Cancer Scale [37] rather 
than the mini-Mental Adjustment to Cancer Scale [38]); (ii) an additional measure 
was required to assess psychological flexibility, our hypothesised mediator of 
intervention effect; and (iii) a UK-specific measure of health resource utilisation was 
needed for context-specific health economic assessment. 
 
Primary Outcome 
Our primary trial outcome variable is cancer-specific distress. For this 
variable, we will use the Post-Traumatic Stress Scale [39], a 17-item measure in 
which participants respond on a 4-point Likert scale, where responses are anchored 
from 0 (“Not at all or only one time”) to 3 (“5 or more times per week / almost 
always”). The Post-Traumatic Stress Scale is associated with excellent internal 
consistency reliability ( = .91) [39] and has good concurrent validity, including 
strong positive correlations with other measures of trauma-related intrusion and 
avoidance, anxiety, and depression [39]. Higher scores on the Post-Traumatic 
Stress Scale indicate greater severity of cancer-specific distress. 
 
Secondary outcomes 
Psychological Wellbeing. The Depression, Anxiety, and Stress Scales, 21-
item version (DASS-21) [40] is a short measure of negative emotions experienced 
over the course of the past week for the individual. Each item is presented as a 4-
point Likert scale, anchored from 0 (“Did not apply to me at all”) to 3 (“Applied to me 
very much or most of the time”). Total scores for each subscale of the DASS-21 can 
be calculated where higher scores indicate greater levels of depression, anxiety, and 
stress, respectively. The scale has good internal reliability (depression  = .91; 
anxiety  = .81; stress  = .89), and concurrent validity, including strong, positive 
correlations with other measures of depressive symptoms and anxiety (Lovibond & 
Lovibond, 1995). 
Quality of Life. The European Organisation for Research and Treatment of 
Cancer Quality of Life Core Questionnaire (QLQ-C30) [41] is a 30-item quality of life 
assessment for cancer patients, which yields a global quality of life score and five 
functional subscale scores associated with physical, emotional, social, role, and 
cognitive quality of life domains. Twenty-eight items are presented on a 4-point Likert 
scale anchored from 1 (“Not at all”) to 4 (“Very much”). The final two items assessing 
subjective assessment of overall health and quality of life are presented on a 7-point 
Likert scale anchored from 1 (“Very poor”) to 7 (“Excellent”). The global score for the 
QLQ-C30 is associated with good internal consistency reliability ( = .86), and has  
good concurrent validity, with both global quality of life and domain subscales 
significantly positively correlated with performance status throughout treatment [41]. 
A higher global score on the QLQ-C30 indicates greater quality of life. The QLQ-C30 
score can be converted into an indication of QALYs to be used in health economic 
analysis. 
 
 
Table 2. Schedule of questionnaire administration 
 
Variable Baseline 
Assessment 
Mid-point 
Assessment 
Beginning of 6th 
module 
End of 
FMW-UK 
3-Month 
Follow Up 
6-Month 
Follow Up 
Demographic Characteristics ✓      
Cancer-Specific Distress  
(Post-Traumatic Stress Scale) 
✓ ✓  ✓ ✓ ✓ 
Psychological Wellbeing  
(Depression, Anxiety, and Stress Scales 21-item version) 
✓ ✓  ✓ ✓ ✓ 
Quality of Life  
(The QLQ-C30 Questionnaire) 
✓ ✓  ✓ ✓ ✓ 
Psychological Adjustment to Cancer  
(The PIC Scale) 
✓ ✓  ✓ ✓ ✓ 
Healthcare Utilisation  
(The UK Cancer Costs Questionnaire) 
✓ ✓  ✓ ✓ ✓ 
Perceived Social Support  
(The MOS Social Support Survey) 
✓      
Emotion Regulation  
(Difficulties in Emotion Regulation Scale) 
✓      
Information Seeking Preferences  
(The Miller Behavioural Style Scale) 
✓      
Psychological Flexibility  
(The CompACT Questionnaire) 
✓ ✓  ✓ ✓ ✓ 
Engagement with Intervention  
(Self-Help Compliance Scale) 
  ✓    
 
 
Psychological Impact of Cancer. The Psychological Impact of Cancer Scale 
(PIC) [37] is a 12-item self-report measure of psychological adjustment to cancer. 
Each item is presented on a 4-point Likert scale anchored from 1 (“Definitely does 
not apply to me”) to 4 (“Definitely applied to me”). The PIC yields four subscale 
scores: Cognitive Distress, Cognitive Avoidance, Emotional Distress, and Fighting 
Spirit. Greater scores on each subscale indicate greater levels of the named 
construct (e.g., a greater score on the Cognitive Distress subscale indicates greater 
levels of cognitive distress). The Fighting Spirit subscale will not be included due to 
underlying psychometric property issues [37]; the remaining three scales have 
reasonable internal consistency reliability (  .62) and good concurrent validity with 
longer measures of psychological adjustment to cancer [37]. 
The UK Cancer Costs Questionnaire. The UK Cancer Costs Questionnaire 
[42] is a flexible modular self-report measure of resource use by people with cancer 
and people with a previous diagnosis of cancer. The UK Cancer Costs Questionnaire 
assesses employment status, family support provided, government benefits 
received, and support provided by other organisations over the previous three 
months. The UK Cancer Costs Questionnaire prioritises brevity to minimise the 
burden of data collection for participants. For full healthcare utilisation outcome data, 
this self-report questionnaire is supplemented by health service resource use data 
extracted from clinical records, and the calculation of QALYs from the QLQ-C30. 
 
Potential intervention moderator / mediators 
In psychological intervention research it is important to include measures of 
the hypothesised variables being acted upon in order to (a) verify cause-and-effect 
relationships on outcome improvements, and (b) identify any important moderator 
and mediator analyses that may need to be undertaken [13]. The following 
measures have been identified as likely moderators of the effectiveness of the 
intervention, and have been informed in large part by a moderator analysis of the 
Australian FMW Trial [43]. 
Perceived Social Support. The Medical Outcome Study (MOS) Social 
Support survey [44] is a 20-item measure, with items presented as a 5-point Likert 
scale anchored from 1 (“None of the time”) to 5 (“All of the time”). The MOS Social 
Support Survey yields four subscale scores: emotional/informational support, 
tangible support, affectionate support, and positive social interactions. Each 
subscale is associated with excellent internal consistency reliability ( > .91) [44]. 
The MOS Social Support Survey is associated with good convergent validity with 
measures of family ties, family functioning, and mental health and good divergent 
validity with measures of purely physical health [44]. Higher scores on individual 
subscales and the overall support index indicates more social support. 
Emotion Regulation. The Difficulties in Emotion Regulation Scale [45] is a 
36-item self-report measure of six dimensions of emotion regulation difficulties: lack 
of awareness of emotional responses, lack of clarity of emotional responses, non-
acceptance of emotional responses, limited access to emotion regulation strategies 
perceived as effective, difficulties controlling impulses when experiencing negative 
emotions, and difficulties engaging in goal-directed behaviours when experiencing 
negative emotions. Each item is presented as a 5-point Likert scale anchored from 1 
(“Almost never”) to 5 (“Almost always”). The global difficulties in emotional regulation 
scale is associated with excellent internal consistency reliability ( = .93) and each 
subscale is associated with good internal consistency reliability ( > .80) [45]. The 
difficulties in emotion regulation scale is associated with good construct validity and 
predictive validity [45]. Higher scores on the Difficulties in Emotion Regulation Scale 
indicate greater problems with emotion regulation. 
Information Seeking Preferences. The Miller Behavioural Style Scale [46] is 
a self-report measure of information seeking preferences. The scale identifies 
individual preferences for seeking threat-related cues (monitors) versus seeking 
distraction to minimise exposure to threat-related cues (blunters). The scale prompts 
participants to imagine four stressful scenarios, each of which is followed by eight 
statements that describe different ways of coping with the stressor. Participants are 
asked to select all statements that apply to them. The Miller Behavioural Style Scale 
is associated with good test-retest reliability over a 4-month period (monitoring 
subscale r = .72; blunting subscale r = .75) and high construct validity, as indicated 
by high correspondence with information-seeking behaviour in a stress-inducing 
laboratory task [46]. Higher scores on the Miller Behavioural Style Scale indicate 
greater tendencies for monitoring, rather than blunting, information seeking 
preference. 
Self-Help Compliance. The Self-Help Compliance Scale [47] is a brief 
measure assessing engagement with self-guided psychological interventions. The 
scale consists of 3 items presented on a 5-point Likert-type scale assessing the 
amount of information participants read (anchored from “0%” to “100%”), the number 
of suggestions and worksheets participants completed (anchored from “0%” to 
“100%”), and how much time participants spent using the programme per week 
(anchored from “None” to “61+ minutes”). The questionnaire also includes one open 
question asking participants what other psychological treatment they have received 
during the programme. 
 
We also predict that psychological flexibility will mediate the effect of the UK-adapted 
Finding My Way intervention. We have operationalised psychological flexibility using 
the CompACT [48]. 
 
Psychological Flexibility. The CompACT [48] is a 23-item self-report 
measure of psychological flexibility, allowing calculation of sub-scale scores for (i) 
openness to experience, (ii) behavioural awareness, and (iii) valued action. Each 
item is presented as a 7-point Likert scale anchored from 0 (“Strongly disagree”) to 6 
(“Strongly agree”). The CompACT has adequate internal consistency reliability 
(average inter-item correlation, r = .34), good convergent validity and good 
discriminant validity [48]. Higher scores on the CompACT indicate greater 
psychological flexibility. 
 
Embedded qualitative interviews 
We will purposively recruit 20-30 participants from the intervention group 
(ensuring a range of age, gender, cancer type, and website engagement) to take part 
in a semi-structured interview two-to-four weeks after trial completion. Semi-structured 
interviews will be used to allow flexibility in the focus of interviews for each participant 
[49], and in-depth probing of individuals’ experiences using the FMW-UK website, and 
factors that affect acceptability and engagement. Participants willing to take part in this 
embedded study will be offered the option to complete the interview in person (either at 
the University or in their own home) or via telephone or video call, provided the chosen 
interview mode adheres to any government and workplace Covid-19-related social 
distancing rules at the time. Any travel costs will be reimbursed. Our interview topic 
guide will probe for participants’ frequency of website use and, if applicable, reasons for 
low use, overall evaluation and perceived usefulness of the Finding My Way 
programme, and any suggestions for improvement; these are important components of 
acceptability and will be used to inform both refinements of the intervention materials, 
and any planning for implementation, after the trial is complete. All qualitative 
interviews will be audio recorded and transcribed verbatim for later analysis. 
 
Analysis 
The analysis plan matches the Australian FMW RCT [27] as closely as possible. 
Members of the research team involved in the analysis will be blinded to condition 
allocation until the end of the trial. We will first conduct data cleaning to ensure that all 
data values are possible and plausible. Errant data entries will be deleted from the final 
analysis data set and missing data will be handled using either pro-rating or imputation 
methods as is (a) appropriate to the collected data, and (b) congruent with the specific 
scoring instructions for the psychometric measure from which there is a missing 
response. 
Descriptive statistics will be used to provide sample characteristic information, 
and to identify any potentially prognostic demographic or clinical co-variates. Inferential 
statistical analyses are powered to undertake Mixed Model Repeated Measures 
analyses to examine intervention effects on change from baseline to follow-up for each 
outcome, using intention-to-treat analysis. Two models will be run for each: (i) 
unadjusted, accounting for co-variance of baseline measures of outcomes; and (ii) fully 
adjusted, controlling for all potential confounding variables assessed. Where possible 
and adequately powered, we will include potential confounders in our analyses and 
evaluate the effects of missing data using Sensitivity Analysis. Cohen’s d effect sizes 
reflect intervention effects, and clinically significant changes will be assessed using 
Reliable Change Indices. The healthcare utilisation outcome will be summarised 
descriptively for activity counts and cumulative costs estimated by assigning unit 
costs to units of activity. Cost summaries will be made from discrete payer 
perspectives. Generalised linear models will be used to adjust for the same 
confounding variables as the efficacy analysis. All quantitative data analyses will be 
undertaken in R software [50] where possible, with any supplementary analyses 
conducted in SPSS as appropriate.  
Qualitative data collected during the embedded qualitative interviews will be 
analysed using thematic analysis [51]. In accordance with best practice guidance for 
thematic analysis, analysis will be undertaken by one member of the local research 
team with a proportion audited independently by a second researcher. A small sub-
group of the Trial Steering Group will then be convened to agree the resultant 
themes which emerge. Qualitative analysis will be managed using NVivo software.  
 
Data Sharing Plan 
As part of our commitment to transparent open science practices, 
anonymised quantitative datasets generated from the Trial will be stored and made 
available through the Open Science Framework following publication of trial findings. 
These data will include the primary and secondary outcome measures, demographic 
and clinical data, as well as any moderating or mediating variables we ultimately 
include in all planned and exploratory analyses. We will not include the name of 
participants’ recruiting cancer centre in the interest of maintaining participant 
anonymity. Participants will be asked to explicitly consent for their anonymised data 
to be shared with other members of the research community in this way. 
Given the focused nature of the qualitative interview schedule (i.e., 
engagement with, views on, and suggestions for improving FMW-UK), and the ethical 
risks involved in releasing qualitative data openly due to the difficulties in adequately 
de-identifying data, we do not currently plan to share data from this aspect of the trial. 
We will, however, review best practice guidelines as they change over the course of 
the project, and review this aspect of the data sharing policy at the time of project 
completion. 
 
Monitoring of Adverse Events 
 We have risk-assessed the potential for serious adverse events from this 
clinical trial to be low. Where a member of the research team is contacted by a 
participant reporting an adverse event (including elevated psychological distress), 
they will follow a standard protocol to assess the seriousness of the situation. In the 
case of disclosure of suicidality and immediate safety concerns, the researcher will 
contact emergency services and remain on the telephone with the participant until 
they arrive. In all other cases, the researcher will provide signposting to additional 
psychological support available as part of standard care, including to the GP and 
clinical team. All adverse events will be reported to the Principal Investigator who will 
assess the severity of the event and report it to the study sponsor (and NHS REC in 
the case of a serious adverse event). Provided that participants have provided 
consent for us to do so, we will also report the adverse event to the clinical team via 
the recruiting CRN RN so that a member of the relevant care team can contact the 
participant to ensure that appropriate support is put into place. 
 
Ethical approval and trial registration 
Ethical review was sought from the University of Chester Department of 
Psychology Ethics Committee to trigger agreement from the University to act as Study 
Sponsor. Full approval was then gained from an NHS Research Ethics Committee 
(REC Reference: 21/WA/0029), leading to Health Research Authority (HRA) approval, 
followed by site-specific research governance approvals at each site. As one of our 
sites is in Wales, professional Welsh translations of study information are being 
provided for use at that site, in accordance with the Welsh Language Act (1993) [52]. 
The trial was registered on the ISRCTN (Reference: ISRCTN14317248; Date 
Registered 08/04/2021). We have established a Trial Profile on the Open Science 
Framework (DOI 10.17605/OSF.IO/ZSHBQ; Date Registered: 18 May 2021) to 
facilitate the later sharing of data. The trial is designed in accordance with principles for 
medical research involving human subjects as laid down in the World Medical 
Association Declaration of Helsinki. 
 
RESULTS 
 
 The grant for this trial was awarded by North West Cancer Research in 
September 2019. The project commenced in April 2020, but initial progress was 
slower than expected due to the impact of Covid-19 pandemic on health research in 
the UK [53]. 
 
User testing of the adapted FMW programme 
All intervention adaptation work was completed by January 2021. User 
feedback from our panel of three healthcare professionals and four cancer survivor 
volunteers was then collated. The overall response was positive with healthcare 
professionals noting that the programme was helpful and supportive and that they 
would recommend it to their patients. The cancer survivors also praised the 
programme, stating unanimously that they wished they had had access to something 
similar during treatment. Some minor changes were recommended, as summarised 
below.  
First, a number of technical issues were highlighted and corrected, including: 
• The website tutorial and resources tab were made to be more 
prominently visible, through altered placement and graphical 
appearance on the webpage. 
• Some navigational issues were also highlighted, with some links not 
working and others navigating to the wrong page. 
• The embedded YouTube videos were set up as playlists, which means 
that each one, on completion, linked to the next video in the playlist 
giving a preview to what was to come in other modules. There is an 
option in YouTube to easily disable this feature.  
• Linked content was reprogrammed to launch in a new tab to prevent 
users becoming lost in the underlying web architecture.  
Second, user feedback highlighted some areas where the content could be 
more inclusive. For example, some occurrences of gendered language were 
replaced with more inclusive language (they/them), and the skin tone of some 
cartoon images was varied to represent the population diversity of our target 
recruitment area. Minor changes were made to correct a perceived bias towards 
breast cancer, and to be more inclusive of those without a faith belief or religion. 
Third, some aspects of terminology were perceived as outdated (e.g., “taking 
the telephone off the hook”) and were thus replaced (e.g., “turning your mobile off”). 
Similarly, recommendations for meeting new people and maintaining social support 
were updated to reflect the drive towards social media over traditional media. Some 
minor changes were made to the language used to refer to different types of 
healthcare professional used in the UK healthcare system.  
Finally, changes were recommended to the flow of the Improving 
Communication page and a greater range of linked/recommended charities and 
support organisations were added to the support pages. One participant 
recommended changes to the Sexuality and Intimacy section related to safe sex 
practices during cancer treatment, which were then researched and re-written by our 
team to align with current NHS guidance [54].  
 
Clinical Trial Progress 
We launched recruitment for the clinical trial in late April 2021, initially at our 
two largest hospital centres. The remaining sites will begin recruiting from Summer 
2021. We plan to complete recruitment by February 2022, with all follow-up 
quantitative data collection completed by October 2022 and all qualitative interviews 
completed by December 2022. Data analysis will then take place. We aim to report 
on the findings from the trial from Spring 2023. 
 
DISCUSSION 
 
The FMW programme of psychological support has so far yielded promising 
results amongst recently diagnosed adult cancer survivors in Australia [25–27]. 
However, the adaptation work described in the current protocol was necessary to 
make this programme suitable for implementation in the UK. Including equipment, 
web-design, videography, and patient and public reimbursement, our adaptation 
work has costed in the region of £25,000 (excluding staffing costs); taking 
approximately 10 months to complete. This was a considerable undertaking but still 
represents a very substantial cost saving compared with developing a new 
intervention from scratch [55,56]. These efforts were important and justified given 
the positive feedback reported by our user testing group. Importantly, our approach 
to adaptation of the website content allowed us to adopt some elements of co-design 
with patient experts [57], as is recommended by the UK National Institute for Health 
Research [58]. This approach to close—and active—partnership work with our 
broader expert stakeholders will not only increase the acceptability of our adaptation 
[59], but will also enhance the possibility for later implementation and impact [60] 
across the UK, should our current trial demonstrate efficacy.    
The FMW-UK clinical trial, which is now underway, will test the efficacy of this 
programme in reducing cancer-specific distress, improving wellbeing, and reducing 
the need for broader healthcare utilisation. As much as possible we have retained (or 
improved) features of the original Australian RCT to ensure that our work can act as 
a replication trial. Replication studies are an important aspect of the scientific 
process [61] and have an important place in psychological [62], broader health 
sciences [63], and clinical trials [64] literature. Our mixed-methods design is 
important to the integrity of our trial, and offers not only efficacy and cost-
effectiveness information, but information on the sociocultural context and lived 
experiences of participants engaged in the intervention too [65].  
If our UK-based trial does indeed replicate the Australian findings, then this 
research study will have identified a novel and cost-effective method of psychosocial 
care delivery for cancer survivors in the NHS. This will of course be limited to those 
particular sites from which we are recruiting (i.e., in North West England and North 
Wales) and so some additional work may need to be undertaken to explore potential 
barriers and appropriate pathways for rapid implementation and evaluation across 
other parts of the UK. 
 
Dissemination Plans 
To contribute to the transparency of our clinical trial a full and detailed trial 
protocol is available as an open resource through the Open Science Framework 
(DOI 10.17605/OSF.IO/ZSHBQ). 
Our primary scientific dissemination will be through high-quality peer-reviewed 
journal articles and relevant National and International conferences. We will prioritise 
journals and conferences that maximise dissemination to cancer care clinicians as well 
as psychosocial oncology researchers. Our study is registered on the NIHR CRN 
Cancer Portfolio, and we will work with the NIHR, NHS sites involved in recruitment, 
and with our existing network of charity partners to maximise dissemination 
opportunities. We will ensure dissemination to the public through regular newsletters to 
trial participants and an annual public lecture event. Our cancer survivor co-investigator 
will be part of the authorship team for all of our dissemination activities, and we aim to 
include our additional patient, carer and healthcare stakeholders on the Trial Steering 
Group in contributing to lay summaries and public dissemination activities. 
On completion of the FMW-UK Trial, our dedicated YouTube channel containing 
both healthcare professional and edited cancer survivor videos will be publicly listed to 
ensure maximised societal benefit. 
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